TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ZAMBON SPA

RespiratoryNeurologyCardiovascular
Pharma

ZAMBON SPA is a pharmaceutical company focused on Respiratory, Neurology, Cardiovascular.

1996
Since
4
Drugs
-
Trials
21
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

OLOPATADINE HYDROCHLORIDE 2026-01-06
DORZOLAMIDE HYDROCHLORIDE 2025-10-01
Labeling
DORZOLAMIDE HYDROCHLORIDE 2025-10-01
Labeling
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-09-03
Labeling
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-09-03
Labeling
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-08-22
Labeling
OLOPATADINE HYDROCHLORIDE 2025-07-14
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-06-17
Labeling
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-06-17
Labeling
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE 2025-05-27
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 29%
0 drugs Phase 3: 2 Phase 1: 2
Neurology 26%
0 drugs Phase 3: 2 Phase 1: 1
Cardiovascular 17%
1 drugs
Ophthalmology 17%
1 drugs
Dermatology 11%
0 drugs Phase 3: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Novartis big-pharma
Cardiovascular, Ophthalmology, Respiratory
Baxter specialty
Cardiovascular, Dermatology, Ophthalmology
LEDERLE big-pharma
Cardiovascular, Neurology, Dermatology, Respiratory
Bayer big-pharma
Cardiovascular, Ophthalmology, Dermatology
Roche big-pharma
Neurology, Ophthalmology, Respiratory